Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The management discussed sitting on a large cash pool and currently not finding suitable opportunities to invest that money for business expansion. They are exploring inorganic growth opportunities but have not specified any active fundraising plans. Capex plans are modest, mainly focused on R&D and maintenance, with about INR10-15 crores expected annually. No direct indications of fresh equity issuance or debt raising for growth or capacity expansion were mentioned as of now.

Any current/future capex/capital investment/strategic investment?

Current capex is low, with INR5 million spent in the first half of FY24 compared to INR28 million last year. Annual maintenance capex is expected around INR10-15 crores. For capacity expansion, a planned capex of INR40-50 crores is expected over one to two years. Capacity expansion will be considered once utilization reaches about 80%. Expansion focus remains on core business areas: animal feed, nutraceuticals, probiotics, and biocatalysts. The company is investing in an R&D center in Nashik; operational expected in 1.5 years, with expenses rising until then. Strategic inorganic growth is bein

Future growth expectations in sales/revenue/volumes?

The company expects double-digit CAGR sales growth over the next five years (Page 19, Mukund Kabra). Growth focus is mainly on international markets, especially the U.S., with new product launches in innovative and nutraceutical areas expected to drive future growth (Pages 11-12). Domestic sales growth areas include biocatalyst, food, animal nutrition, and probiotics segments, with the company maintaining over 80% market share in India (Pages 8-9). Capacity utilization is increasing and expected to reach about 70% by the next quarter-end; peak revenue from current capacities is estimated aroun

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects double-digit sales growth CAGR over the next five years (Mukund Kabra, page 19). EBITDA margins are anticipated to improve sequentially from current levels (around 33%) as U.S. markets begin to contribute more significantly (Mukund Kabra, pages 8-9). Return on Equity (ROE) improvement is targeted, with efforts focusing on better utilization of cash balances either through organic or inorganic growth (Beni Prasad Rauka, page 16). Capacity utilization is expected to reach about 70% by the coming quarter, enabling better operating leverage and margin expansion (Mukund Ka

Advanced Enzyme Technologies LtdQ2 FY24Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹262P/E: 18.6Market Cap: ₹2.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects double-digit CAGR sales growth over the next five years (Page 19, Mukund Kabra).
Growth focus is mainly on international markets, especially the U.S., with new product launches in innovative and nutraceutical areas expected to drive future growth (Pages 11-12).
Domestic sales growth areas include biocatalyst, food, animal nutrition, and probiotics segments, with the company maintaining over 80% market share in India (Pages 8-9).
Capacity utilization is increasing and expected to reach about 70% by the next quarter-end; peak revenue from current capacities is estimated around INR 800-900 crores (Page 6).
The company anticipates better growth in international markets as global trade challenges ease (Page 11).
Some near-term challenges like geopolitical tensions and inflation may impact growth, but management expects improved margins and revenue sequentially going forward (Pages 3, 8, 14, 19).

Margin guidance

Category 2

The company expects double-digit sales growth CAGR over the next five years (Mukund Kabra, page 19).
EBITDA margins are anticipated to improve sequentially from current levels (around 33%) as U.S. markets begin to contribute more significantly (Mukund Kabra, pages 8-9).
Return on Equity (ROE) improvement is targeted, with efforts focusing on better utilization of cash balances either through organic or inorganic growth (Beni Prasad Rauka, page 16).
Capacity utilization is expected to reach about 70% by the coming quarter, enabling better operating leverage and margin expansion (Mukund Kabra, page 6).
Margin expansion towards previous higher levels (approximately 35%-40%) is expected over medium-term but may take some time beyond FY24 (Mukund Kabra, pages 7-8).
Growth will be driven mainly by international markets, nutraceuticals, probiotics, and food enzyme segments (multiple mentions including pages 8-12).

See what Advanced Enzyme Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The management discussed sitting on a large cash pool and currently not finding suitable opportunities to invest that money for business expansion.
They are exploring inorganic growth opportunities but have not specified any active fundraising plans.
Capex plans are modest, mainly focused on R&D and maintenance, with about INR10-15 crores expected annually.
No direct indications of fresh equity issuance or debt raising for growth or capacity expansion were mentioned as of now.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for Advanced Enzyme Technologies Limited. However, relevant insights include: - The company expects a double-digit sales growth CAGR over the next five years (Mukund Kabra). - Capacity utilization is increasing and expected to reach around 70% by the coming quarter end, indicating healthy demand (Mukund Kabra). - Peak revenue from current capacities is estimated around INR 800-900 crores, subject to product mix (Mukund Kabra). - Growth is driven largely by domestic demand and biocatalyst, food, animal feed, and probiotic segments. - The company is focusing on organic growth, supplemented by possible acquisitions. - No explicit order book or pending order values were disclosed during the call. If you need further details on order book status, please let me know!

See what Advanced Enzyme Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current capex is low, with INR5 million spent in the first half of FY24 compared to INR28 million last year.
Annual maintenance capex is expected around INR10-15 crores.
For capacity expansion, a planned capex of INR40-50 crores is expected over one to two years.
Capacity expansion will be considered once utilization reaches about 80%.
Expansion focus remains on core business areas: animal feed, nutraceuticals, probiotics, and biocatalysts.
The company is investing in an R&D center in Nashik; operational expected in 1.5 years, with expenses rising until then.
Strategic inorganic growth is being explored, though major focus remains on organic growth.
Large cash reserves are available, but suitable investment opportunities are still being sought for better returns.

Track Advanced Enzyme Technologies Ltd — get its next earnings analysis in your feed

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAdvanced Enzyme Technologies Ltd

Rev 3Mar 2

See where Advanced Enzyme Technologies Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Advanced Enzyme Technologies Ltd rank in Pharmaceuticals & Biotechnology?

Compare Advanced Enzyme Technologies Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Advanced Enzyme Technologies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →